BioSpace News Archive

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the JMP Securities Life Sciences Conference being held June 15 – 16, 2022 at the Lotte New York Palace in New York City.

Tempest Therapeutics, Inc. (Nasdaq: TPST), today summarized key takeaways from the TPST-1120 clinical program provided by Mark Yarchoan, M.D., associate professor of oncology at Johns Hopkins School of Medicine, at its June 5th investor event held in connection with the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Tryp Therapeutics , Inc. announced today the initial data readout for the first patient dosed in its Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial.

Ambys Medicines , a company pioneering cell-replacement therapies for patients with liver disease, today announced that data from its universal hepatocyte program will be presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, which will be held June 15-18, 2022, in San Francisco and virtually.

Lundbeck to Present Data on VYEPTI ® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention.

Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, announced today the launch of the company with $4 million in seed financing from Academy Investor Network, Fred Moll, and several other prominent angel investors.

Relation Therapeutics announced today that it had raised a $25 million investment and hired a Chief Executive Officer and Chief Technology Officer.

BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans.

Annovis Bio’s Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company’s Lead Compound, to Treat Neurodegenerative Diseases.

Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Health Corp. (NEO:FH) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States.